Fig. 2
From: PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma
PKM2 protein expression profiles in tissue samples obtained from patients with HC at different stages. a, expression of PKM2 in cholangitis, biliary intraepithelial neoplastic lesion (IEN), primary tumor, invasive tumor, and metastatic tumor samples. b, the mean ± SD intensity of PKM2 staining in the samples increased with the progression of HC: 0.36 ± 0.48 in cholangitis, 0 in IEN, 0 in stage I, 1.11 ± 1.11 in stage II, 1.61 ± 1.26 in stage III, and 2.00 ± 1.25 in stage IV samples. c, the PKM2-positivity rates in cholangitis, hyperplasia, and stage I, II, III, and IV samples were 14 % (4/28), 0 % (0/3), 0 % (0/6), 52 % (16/31), 60 % (27/45), and 67 % (4/6), respectively